12 of 50 patients with Leigh's encephalopathy, excluding those with cytochrome oxidase or pyruvate dehydrogenase deficiencies, had the NARP mutation.7 A second mutation at position 8993 (T-C) has also been associated with Leigh's encephalopathy.9
Cycling conditions were 94°C for 3 min, then 30 cycles of 94°C (30 sec), 55°C (30 sec), and 72°C (30 sec). PCR products were digested with AvaI or HpaII under conditions recommended by the manufacturers (Promega), and separated in a 3-2% agarose gel; in the presence of the 8993 mutation the 553 base pair product is digested into two of 347 and 206 base pairs. For quantification, total genomic DNA was digested with HpaII and separated on a 1 6% agarose gel. The gel was Southern blotted and hybridised to an mtDNA PCR product spanning 8646-9199 base pairs labelled with 32P by the random primer method (Amersham) and analysed on a Phosphor-Imager (Molecular Dynamics).
Results
The results of quantitative mtDNA analysis were as follows (proportion of mutant mtDNA): IIf2 (78%); III2 (88%); III-4 (86%); III5 (87%); III6 (93%); III-7 (93%). No blood or tissue samples were available from other family members.
Discussion
The family described here shows exceptionally high penetrance, even for an mtDNA disorder, of the phenotype associated with the NARP mutation, including Leigh's encephalopathy. Until recognition of this syndrome, no connection had been made between the presence of retinitis pigmentosa in the children's mother and uncle and their severe neurological disease. We report this family largely to emphasise the possibility of this underlying mtDNA defect in children with Leigh's encephalopathy, or non-specific delayed development and more mild neurological dysfunction, particularly with pigmentary retinopathy, especially if they have relatives with much milder neurological or ophthalmological disease. Three of the children in our family were initially thought to have cerebral palsy on the basis of their mild and non-progressive neurological dysfunction. Cerebral palsy is a syndrome and not a specific diagnosis and has many different aetiologies; the recurrence of cerebral palsy in siblings or other family members should always raise the suspicion of an underlying, genetically determined disorder. In addition, any child who shows evidence of progressive neurological impairment, with or without acute exacerbations after intercurrent infections, should be considered to have an underlying metabolic or degenerative disease and not 'cerebral palsy'.
In this family, the possibility of a maternally inherited neurological disorder was not seriously considered (by the parents or medical practitioners) until after the birth of the seventh child. One possible explanation for this lies in the marked intrafamilial variation of clinical features; the mother's syndrome was primarily ophthalmological, two of her children (III-1 and III3) showed a rapidly progressive course with early death and two others (III-2 and III5) have shown (predominantly) speech and language impairment.
As in other reported families, a muscle biopsy sample did not show the typical features of a mitochondrial encephalomyopathy (ragged red fibres) in the only family member studied. Evidence of metabolic acidosis with increased plasma and lactate concentrations is variable in severely affected children with this disorder, and usually absent in adults with milder phenotypes. Lactate may be increased in the cerebrospinal fluid (although normal in plasma), but this was not measured in our patients.
There was some correlation between disease severity in this family and the proportion of mutant mtDNA in blood in that the mildly affected mother had 78% mutant mtDNA and all her affected children had levels greater than 85%. Within this sibship, the two most severely affected children available for study had more than 90/o mutant mtDNA. These results are roughly in accord with the findings of Tatuch et al, who concluded that most patients will show early developmental delay where the percentage of mutant mtDNA exceeds 90%,8 whereas milder forms of the disease are associated with 80% mutant mtDNA; below 75% retinal dystrophy is likely to be the only feature. Subjects with less than 50% mutant mtDNA are likely to be asymptomatic.
As appears to be true in other families,7 10 the NARP mutation appears to segregate to high levels of mutant mtDNA rapidly within pedigrees. Accordingly, it seems that the mother of a severely affected child has a high risk of having further children with a high proportion of mutant mtDNA and a severe phenotype. The reason for this is unclear, although segregation to almost 100% mutant mtDNA is a feature of the mtDNA mutations causing Leber's hereditary optic neuropathy." I It is possible that the other members of generation II who died in infancy had the severe form of NARP. Detection of this mutation is important in the diagnosis of Leigh's encephalopathy, or in children with a less specific neurological disorder (including unexplained 'cerebral palsy'), particularly if there is a maternal or family history of neurological or eye disease, or premature death, and obviously has implications in terms of genetic counselling.
